An Optimized Methodology for Patient-Specific Therapeutic Activity Administration in Liver Radioembolization

Radioembolization (RE) with glass microspheres (MS) loaded Yttrium-90 (90Y) has been used to treat tumors in the liver some reported success. However, assessing absorbed doses (AD) planning tumor volume (PTV) and normal (NLV) is a key problem address RE. In clinical practice, computation of 90Y activity be administered follows manufacturer’s recommendations, which do not consider specific characteristics MS deposition each patient’s liver. Our main aim develop methodology estimate optimal for patient treatment. It uses dose distribution (ADD) derived from Technetium-99m (99mTc)-labeled macroaggregated albumin (MAA) obtained pre-treatment single-photon emission computed tomography (SPECT) images. Post-treatment positron (PET) images 90Y-MS were ADD treatment verification. Sixteen RE treatments retrospectively selected. The agreement between estimated mean AD based on imaging real post-treatment was good PTV an intraclass correlation coefficient (ICC) 0.79 excellent NLV (ICC = 0.97). optimization using pre-defined thresholds (<70 Gy >80 PTV) imposed voxels showed remarkably high 0.96, p < 0.001) eleven out sixteen SPECT-MAA-based PET-MS-based estimates. conclusion, under well-controlled conditions, SPECT-MAA predicts well ADD. addition, can optimize